证券代码：002584 证券简称：西陇化工 西陇化工股份有限公司投资者关系活动记录表 编号：20151101 | --- | --- | --- | |----------------|--------------------------------|----------------------------------------------------| | | | | | 投资者关系活动 | ■ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 安州投资 金梦 | | | 人员姓名 | 融捷资产 李奕 | | | | 广东冠丰资产管理 杨欢、周策 | | | | 广州证券 高传伦 | | | | 海通证券 刘威 | | | | 广东润行投资管理 陈波 | | | 时间 | 2015 年 11 月 16 | 日 10：00 - 12：00 | | 地点 | 董事会秘书办公室 | | | 上市公司接待人 | 邬军晖 | ...

证券代码：002584 证券简称：西陇化工 西陇化工股份有限公司投资者关系活动记录表 编号：20150801 | --- | --- | --- | |----------------|-----------------------------|-----------------------------------------| | | | | | 投资者关系活动 | ■ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 上海汇利资产 叶丽 | | | 人员姓名 | 瑞锐投资 陆慧 | | | | 深圳卓越鼎盛 冯超、王嘉睎 | | | | 中海基金 易小金 | | | | 北京宏道投资 张海滨 | | | | 中国健康产业投资基金 应振洲 | | | | 中国人寿资产 丁天宇 | | | | | 华泰证券 杨烨辉、肖汉山、陈虹妃、朱荣钊 | | | 广东新价值 林帅 | | | | 九泰基金 林柏川 | | | | ...

证券代码：002584 证券简称：西陇科学 西陇科学股份有限公司投资者关系活动记录表 编号：20151101 | --- | --- | --- | |----------------|-------------------------------|----------------------------------------------------| | | | | | 投资者关系活动 | ■ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 太平洋证券 杨林 | | | 人员姓名 | | | | 时间 | 2016 年 1 月 4 | 日 14:00-16:00 | | 地点 | 董事会秘书办公室 | | | 上市公司接待人 | 邬军晖 | | | 员姓名 | 莫娇 | | | | 1. 公司的历史和发展过程简介 | | | | | 公司正在进行生产模式的转变，从传统的生产型企业转向 | | | | 轻资产的生产 ...

证券代码：002584 证券简称：西陇科学 西陇科学股份有限公司投资者关系活动记录表 编号：20160501 | --- | --- | --- | |----------------|------------------------------|---------------------------------| | | | | | 投资者关系活动 | ■ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 澳银资本 纪昌涛 | | | 人员姓名 | 国都证券 赵玥 | | | | 广州证券 邓照 | | | | 通晟资产 张烨 | | | | 华创证券 王逸萌 | | | | 华创证券 宋凯 | | | | 中科沃土基金 孟禄程 | | | | 广东瑞天投资 王贤 | | | | 广发基金 王瑞冬 | | | | 广发资管 毛丁丁 | | | 时间 | 2016 年 5 月 24 日 | 13:30-15:30 | ...

证券代码：002584 证券简称：西陇科学 西陇科学股份有限公司投资者关系活动记录表 编 号 ： 20201222 | --- | --- | --- | |-----------------------|-----------------------------|----------------------------------------------------| | | | | | | ■ | 特定对象调研 □分析师会议 | | | □媒体采访 □业绩说明会 | | | 投资者关系活动 | □ 新闻发布会 □路演活动 | | | 类别 | □现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 华泰证券 王玮嘉 陆晓霞 | | | 人员姓名 | | | | | | | | 时间 | 2020 年 12 月 22 | 日 10： 15 - 12 ： 00 | | 地点 | 公司 5 楼会议室 | | | 上市公司接待人 员姓名 | 宗岩 | | | | 1. 公司所处行业发展情况？ | | | | | （1）化学试剂行业的一个重要特点是品种多，工艺技术 | | ...

证券代码：002584 证券简称：西陇科学 编号：2022-02 西陇科学股份有限公司 投资者活动记录表 | --- | --- | --- | |-----------------------------|--------------------------------------------------|----------------------------------------------------------------------------------------------------| | | □特定对象调研 □分析师会议 | | | | □媒体采访 | □业绩说明会 | | 投资者关系活动 | □新闻发布会 □路演活动 | | | 类别 | □现场参观 | □电话会议 | | | √其他： 2022 | 广东辖区上市公司投资者网上集体接待日 | | 参与单位名称 及人员姓名 | 西陇科学 2022 远程方式进行，面向全体投资者 | 广东辖区上市公司投资者网上集体接待日活动采用网络 | | 时间 | 2022 年 9 月 22 日 15:50-16:50 | | | 地点 | 全景网 | ...

Financial Performance - The company's revenue for Q1 2022 was ¥1,838,144,076.52, representing a 16.24% increase compared to ¥1,581,356,349.46 in the same period last year[3] - Net profit attributable to shareholders reached ¥83,755,330.19, a significant increase of 505.07% from ¥13,842,141.69 in the previous year[3] - Basic earnings per share increased to ¥0.14, up 600.00% from ¥0.02 in the same period last year[3] - Total operating revenue for the first quarter reached ¥1,838,144,076.52, an increase of 16.3% compared to ¥1,581,356,349.46 in the previous year[25] - Net profit for the period was ¥83,957,732.37, significantly higher than ¥11,861,247.73 in the same quarter last year, marking a substantial increase[28] - The total comprehensive income for the period was ¥83,938,253.21, compared to ¥11,549,352.03 in the previous year, showing a strong performance[30] Cash Flow - The net cash flow from operating activities decreased by 70.02% to ¥12,699,955.54, down from ¥42,357,886.65 in the previous year[3] - The net cash flow from operating activities for the current period is ¥12,699,955.54, a decrease of 70% compared to ¥42,357,886.65 in the previous period[35] - The cash outflow from operating activities totals ¥2,133,909,033.81, compared to ¥1,682,987,659.80 in the previous period, indicating higher operational expenses[35] - The net cash flow from investment activities improved to ¥282,179,941.84 from -¥19,932,086.14 in the previous period, indicating a positive turnaround in investment performance[35] - The total cash inflow from investment activities is ¥389,951,398.69, significantly higher than ¥40,195,070.14 in the previous period[35] - The net cash flow from financing activities is -¥194,630,992.88, compared to -¥173,727,365.04 in the previous period, indicating increased cash outflows[35] Assets and Liabilities - The total assets at the end of the reporting period were ¥4,696,696,552.69, a slight decrease of 0.58% from ¥4,724,032,726.87 at the end of the previous year[3] - The company's total liabilities decreased to ¥2,365,626,894.65 from ¥2,402,156,073.62, a reduction of approximately 1.5%[24] - The total equity attributable to shareholders of the parent company rose to ¥2,325,456,355.60, compared to ¥2,241,063,958.72, indicating an increase of about 3.5%[24] - The company's equity attributable to shareholders increased by 3.77% to ¥2,325,456,355.60 from ¥2,241,063,958.72 at the end of the previous year[3] - The total non-current assets decreased to ¥1,020,143,496.87 from ¥1,153,806,494.39 at the beginning of the year[18] Shareholder Information - The total number of common shareholders at the end of the reporting period is 92,999, with the top ten shareholders holding a combined 55.31% of shares[11] - Huang Shaoqun holds 12.73% of shares, with a total of 74,500,000 shares, and has 7,760,000 shares frozen[11] Investment and Development - Investment income surged to ¥72,607,438.26, a remarkable increase of 78303.01% compared to ¥92,607.97 in the previous year[9] - The company has plans for market expansion and new product development, although specific details were not disclosed in the report[27] Tax and Expenses - The company experienced a 371.53% increase in income tax expenses, totaling ¥7,365,387.45, due to the growth in total profit[9] - The company paid ¥22,031,989.51 in taxes, down from ¥49,655,724.82 in the previous period, showing a reduction in tax liabilities[35] Inventory and Current Assets - The company's total current assets amount to ¥3,676,553,055.82, an increase from ¥3,570,226,232.48 at the beginning of the year[15] - Cash and cash equivalents at the end of the reporting period are ¥846,761,942.70, up from ¥769,862,949.87 at the beginning of the year[15] - Accounts receivable stand at ¥1,243,736,953.53, compared to ¥1,212,893,151.92 at the start of the year[15] - Inventory has increased to ¥697,589,849.59 from ¥454,424,458.43 at the beginning of the year[18]

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the year 2021, representing a year-on-year increase of 15%[23]. - The net profit attributable to shareholders was RMB 200 million, an increase of 10% compared to the previous year[23]. - The company's operating revenue for 2021 was ¥6,837,667,633.82, representing a 9.52% increase from ¥6,243,170,933.20 in 2020[6]. - The net profit attributable to shareholders in 2021 was ¥203,877,034.92, a significant increase of 258.47% compared to ¥56,873,463.11 in 2020[6]. - The net cash flow from operating activities was ¥346,617,647.91, marking a 677.67% increase from ¥44,571,222.05 in 2020[6]. - The company reported a significant increase in financial expenses by 66.55% to approximately ¥67.75 million, primarily due to reduced interest income and increased exchange losses[82]. - The company reported a total of 329,793,075.09 yuan in financial assets at the end of the reporting period, with significant transactions in trading financial assets and other equity investments[120]. Research and Development - The company plans to invest RMB 300 million in research and development for new products and technologies in 2022[23]. - Research and development expenses rose by 15.82% to approximately ¥118.97 million, reflecting the company's commitment to innovation[82]. - The company has initiated several key R&D projects aimed at enhancing the purity of electronic chemical products, which are currently in the pilot testing phase[104]. - The company has been awarded 21 patents for general chemical reagents and 13 patents for electronic chemicals, indicating strong R&D capabilities[69]. - The company achieved significant product development, including the mass production of lithium-ion battery adhesives and environmentally friendly high-purity potassium persulfate, with a purity specification of 99.5% HPLC for organic pharmaceutical intermediates[63]. Market Expansion and Strategy - The company has outlined a market expansion strategy targeting Southeast Asia, aiming for a 20% market share in the region by 2025[23]. - The company expects a revenue growth forecast of 18% for 2022, driven by new product launches and market expansion efforts[23]. - The company is focusing on the semiconductor and new energy materials sectors, aligning with the "carbon neutrality" strategy for high-quality development[62]. - The company is actively adjusting its product structure and optimizing production processes to meet stricter environmental standards and reduce emissions[143]. - The company is exploring potential mergers and acquisitions to enhance its product offerings and market presence[23]. Operational Efficiency - The gross margin for the year was reported at 35%, a slight decrease from 37% in the previous year[23]. - The company reported a net profit margin of 12%, up from 10% in the previous year, indicating improved operational efficiency[182]. - The company aims to enhance management efficiency and reduce costs while improving product quality and delivery times through internal management improvements[136]. - The company has established a governance structure that operates independently from its controlling shareholders[162]. User and Market Data - User data showed a growth of 25% in active users of the company's e-commerce platform, reaching 1 million users by the end of 2021[23]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the fiscal year, representing a 20% year-over-year growth[182]. - Market expansion efforts have led to a 10% increase in sales in international markets, totaling 300 million RMB[182]. Corporate Governance - The company has held one annual general meeting and six extraordinary general meetings during the reporting period, ensuring compliance with legal and regulatory requirements[151]. - The board of directors has completed a re-election process, maintaining a structure that complies with legal requirements and includes independent directors[152]. - The company has established a dedicated audit department to conduct regular financial audits in accordance with regulatory guidelines[155]. Asset Management - The total assets at the end of 2021 were ¥4,724,032,726.87, which is a 6.84% increase from ¥4,421,453,856.17 at the end of 2020[6]. - The company’s inventory decreased significantly from CNY 713,335,682.26 at the beginning of 2021 to CNY 454,424,458.43 at the end of the year, reflecting a reduction of 6.51% in its proportion of total assets[116]. - The company has a total of 363,512,479.28 yuan in restricted assets at the end of the reporting period, including 279,454,686.71 yuan in cash and 20,000,000.00 yuan in accounts receivable[123]. Compliance and Regulations - The company has received multiple licenses and certifications, including hazardous chemical operation permits, ensuring compliance with regulatory standards[76]. - The company reported a total of 118 announcements during the reporting period, ensuring compliance with information disclosure regulations[158].

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the year 2020, representing a year-on-year increase of 15%[20]. - The net profit attributable to shareholders was RMB 200 million, which is a 10% increase compared to the previous year[20]. - The company's operating revenue for 2020 was ¥6,243,170,933.20, representing an increase of 87.05% compared to 2019[28]. - The net profit attributable to shareholders for 2020 was ¥56,873,463.11, a growth of 47.62% from the previous year[28]. - The net profit after deducting non-recurring gains and losses reached ¥14,188,964.83, showing a significant increase of 27,107.39% compared to 2019[28]. - The gross margin improved to 35%, up from 30% in the previous year, reflecting better cost management[20]. - The company reported a basic earnings per share of ¥0.10 for 2020, an increase of 42.86% from ¥0.07 in 2019[28]. - The company reported a significant increase in operating costs, which rose by 108.95% to ¥5,584,335,655.13[73]. - The company reported a total operating cost of 5.76 billion CNY under the new standards, compared to 5.70 billion CNY under the old standards[172]. Investment and R&D - The company plans to invest RMB 300 million in R&D for new product development in the upcoming year[20]. - Research and development expenses increased by 17.29% to ¥102,719,157.81, compared to ¥87,580,449.56 in 2019[68]. - The company has been recognized as a "National High-tech Enterprise" and has over 66 independent intellectual property patents, reflecting its strong R&D capabilities[55]. - The company is investing in research and development to strengthen its technical capabilities and respond to market demands effectively[124]. - The company launched new product development initiatives, including semiconductor materials and lithium battery adhesives, enhancing its product service capabilities[63]. Market Strategy and Expansion - The company has outlined a market expansion strategy targeting Southeast Asia, aiming for a 20% market share within three years[20]. - Future guidance estimates a revenue growth of 20% for 2021, driven by new product launches and market expansion[20]. - The company is focusing on industrial upgrades and new project development to maintain market position amid increasing environmental and safety risks in the chemical industry[133]. - The company is committed to developing its core reagent business while expanding into the electronic and health industries[115]. - The company recognizes the rising market potential in the in vitro diagnostic reagent sector, which is entering a growth phase with significant room for development compared to mature markets[119]. Operational Efficiency - The company is actively expanding its production capacity and product range in response to the growing demand for high-purity chemical products in the 5G market[55]. - The company is enhancing its management systems to address the complexities arising from strategic transformations and business expansions[124]. - The company aims to enhance management and data analysis capabilities by optimizing its management structure and operational systems, focusing on improving productivity in marketing and production[116]. - The company is implementing a digital platform, "Tomato CLUB," for internal sales management, enhancing user experience through integrated services[67]. Shareholder Returns and Dividends - The company will not distribute cash dividends or issue bonus shares for the year 2020[7]. - The company reported a net profit attributable to ordinary shareholders of 56,873,463.11 yuan in 2020, with a cash dividend payout ratio of 0.00%[130]. - The company has established a shareholder return plan for 2020-2022, which has been approved by the board and aims to enhance the shareholder return mechanism[129]. - The company has not proposed a cash dividend distribution plan for 2020 despite having positive distributable profits[134]. Risk Management and Compliance - The company faces risks from macroeconomic downturns that could lead to reduced market demand, impacting profits and inventory levels[120]. - Safety production remains a critical concern for the company, which has implemented measures to mitigate risks associated with hazardous materials during production[121]. - The company is actively managing its investment commitments and ensuring compliance with all relevant laws and regulations[164]. - The company has established a risk management framework for its asset management products, ensuring equal rights and risks for all investors[164]. Industry Trends - The IVD market in China is expected to grow at a rate of over 15% due to the ongoing medical reform and the shift towards preventive healthcare[47]. - The electronic chemicals industry is experiencing rapid growth due to the increasing demand from downstream applications such as semiconductors and solar energy, driven by technological advancements[117]. - The overall market concentration in the chemical reagent industry is increasing, with stronger companies rapidly developing to catch up with international leaders[46]. Corporate Structure and Governance - The company is implementing a flat organizational structure to improve management efficiency and support business development[115]. - The company has committed to avoiding competition with its actual controllers and has ongoing commitments related to asset restructuring and refinancing[135]. - The company confirmed that its partners will not accept any financial assistance or guarantees from West Long Chemical[164].

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the fiscal year 2019, representing a year-on-year growth of 15%[16] - The company's operating revenue for 2019 was ¥3,337,661,961.68, a decrease of 0.52% compared to the previous year[24] - The net profit attributable to shareholders was ¥38,527,214.95, representing a significant decline of 45.41% year-over-year[24] - The net profit after deducting non-recurring gains and losses was ¥52,151.14, a drastic drop of 99.71% compared to the previous year[24] - The total operating revenue for 2019 was ¥3,337,661,961.68, a decrease of 0.52% compared to ¥3,355,078,356.99 in 2018[68] - The company reported a total revenue of 3,219.5 million yuan for the period, which fell short of the forecasted 4,000 million yuan[153] Profitability and Margins - The gross profit margin for the year was 35%, indicating a stable profitability despite market fluctuations[16] - The company's gross profit margin in the chemical industry was 13.97%, down by 0.53% from the previous year[73] - The basic earnings per share for 2019 was ¥0.07, down 41.67% from ¥0.12 in the previous year[24] - The diluted earnings per share also stood at ¥0.07, a decrease of 41.67% compared to the previous year[24] - The weighted average return on equity was 2.08%, down from 4.22% in the previous year[24] Cash Flow and Investments - The net cash flow from operating activities was ¥95,892,729.31, showing a remarkable increase of 198.75% from the previous year[24] - The net cash flow from operating activities increased by 198.75% to ¥95,892,729.31, primarily due to the recovery of agency business payments from the previous year[92] - The net cash flow from investing activities rose by 109.49% to ¥27,457,809.71, while there were no acquisition payments in the current period[68] - The net cash flow from financing activities decreased by 89.09% to ¥82,190,957.39, primarily due to reduced borrowings and increased repayments[68] - Cash and cash equivalents net increase was ¥201,298,570.53, a decrease of 45.04% compared to the previous year[92] Research and Development - The company plans to invest RMB 200 million in R&D for new product development in the upcoming year, focusing on advanced chemical products[16] - Research and development expenses amounted to ¥87,580,449.56, which is 2.62% of operating revenue, showing an increase from 2.44% in the previous year[91] - The company has received multiple recognitions as a high-tech enterprise and has over 66 independent intellectual property patents, enhancing its R&D capabilities[52] - The company is committed to increasing R&D investment and enhancing technological innovation to improve core competitiveness[62] Market Strategy and Expansion - The company has outlined a market expansion strategy targeting Southeast Asia, aiming for a 10% market share within three years[16] - Future guidance indicates expected revenue growth of 20% for 2020, driven by new product launches and market expansion efforts[16] - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence[16] - The company expanded its business scope by acquiring stakes in two subsidiaries, increasing its operational footprint[78] Product Development and Offerings - The company has successfully launched a new line of electronic chemicals, contributing to a 30% increase in sales in that segment[16] - The company focuses on the production, R&D, and sales of chemical reagents and has expanded into in vitro diagnostic reagents and gene sequencing services[40] - The company has developed a comprehensive service solution for clients, providing customized chemical reagents and diagnostic kits for various applications, including tumor marker detection and respiratory infection testing[41] - The company expanded its product offerings in molecular diagnostics, with significant growth in sales volume and new installations for specific growth factor detection kits[65] Risk Management - The company has identified key risks including macroeconomic downturns and technological development risks, which will be closely monitored[4] - The company faces risks from macroeconomic downturns, which could impact demand and profitability[123] - Safety production risks are a concern due to the hazardous nature of chemical products, necessitating stringent safety measures[125] - Environmental risks are heightened by stricter regulations, requiring the company to optimize production processes for sustainability[126] Corporate Governance and Compliance - The company did not distribute cash dividends for the years 2017, 2018, and 2019, with net profits of approximately CNY 92.27 million, CNY 70.58 million, and CNY 38.53 million respectively, resulting in a cash dividend payout ratio of 0.00% for each year[134][133][132] - The company has committed to avoiding competition with its actual controllers and has plans in place for the reconstruction of facilities that may be affected by local government planning[142] - The company has confirmed that its business will not compete with the operations of Xilong Chemical after the non-public issuance[149] - The company reported no significant litigation or arbitration matters during the reporting period[174] Industry Trends - The electronic chemical industry is expected to grow rapidly due to the increasing demand from downstream applications such as semiconductors and solar energy[121] - The chemical reagent market is shifting towards specialization and high-end products, driven by increased competition and foreign market entry[122] - The in vitro diagnostic reagent industry is entering a growth phase, with significant market potential remaining untapped compared to developed countries[122]